Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study

MLA

Timothy D. Henry, et al. “Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study.” Cell Transplantation, vol. 25, Sept. 2016, pp. 1701–11. EBSCOhost, https://doi.org/10.3727/096368916x691484.

APA

Timothy D. Henry, Gary L. Schaer, Jay H. Traverse, Thomas J. Povsic, Charles Davidson, Joon Sup Lee, Marco A. Costa, Theodore Bass, Farrell Mendelsohn, F. David Fortuin, Carl J. Pepine, Amit N. Patel, Norbert Riedel, Candice Junge, Andrea Hunt, Dean J. Kereiakes, Christopher White, Robert A. Harrington, Richard A. Schatz, & Douglas W. Losordo. (2016). Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study. Cell Transplantation, 25, 1701–1711. https://doi.org/10.3727/096368916x691484

Chicago

Timothy D. Henry, Gary L. Schaer, Jay H. Traverse, Thomas J. Povsic, Charles Davidson, Joon Sup Lee, Marco A. Costa, et al. 2016. “Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study.” Cell Transplantation 25 (September): 1701–11. doi:10.3727/096368916x691484.